Compare Axium Healthcare Pharmacy vs Implantable Provider Group
Customers evaluate the quality of Axium Healthcare Pharmacy's products using the following success metrics.
Overview
Axium Healthcare Pharmacy is based in United States
Specialty pharmacy Axium Healthcare Pharmacy aims to provide patient-specific drug compounding for bioidentical hormone replacement therapy, dermatology, neurology, orthopedic conditions, podiatry and more.
Implantable Provider Group is 22 yrs old and is based in United States.
On June 29th, 2022, Implantable Provider Group was acquired by Evolent Health at a valuation between $375M and $462M. Implantable Provider Group (IPG) is a nationwide provider of device benefit management (DBM) solutions. As a true benefit manager, IPG's end-to-end DBM solutions serve as a strategic capability for health plans to manage cost and risk in a unique way that drives collaboration between the health plan, its healthcare providers, manufacturers, and physicians to drive lower costs and high-quality care for consumers. The company was founded in 2002 and is based in Alpharetta, Georgia.
Demo Video
Leadership
Mark Montgomery (Chief Executive Officer, President)
Vince Coppola (Chief Executive Officer, President)
Investors
Modern Healthcare, Kroger
Evolent Health, TPG Growth
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because Axium Healthcare Pharmacy has not claimed their profile.
Work for Axium Healthcare Pharmacy? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Axium Healthcare Pharmacy?
Claim your profile now.
Information not available because Implantable Provider Group has not claimed their profile.
Work for Implantable Provider Group? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Implantable Provider Group?
Claim your profile now.
Expert Collections
Digital Health
10,563 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.